| 引用本文:王冠蕾，富大智，王本刚.槐耳颗粒联合吡柔比星介入治疗乙型肝炎肝癌患者的临床疗效[J].世界中医药,2018,(07):. |
|
| 槐耳颗粒联合吡柔比星介入治疗乙型肝炎肝癌患者的临床疗效 |
| Clinical Efficacy Analysis of Huaier Granule Combined with Interventional Treatment on Patients with HBV DNA-negative Hepatitis B |
| 投稿时间：2017-06-19 |
| DOI：10.3969/j.issn.1673-7202.2018.07.009 |
| 中文关键词: 槐耳颗粒 介入治疗 乙型肝炎 肝癌 临床疗效 |
| English Keywords:Huaier granule Interventional treatment Hepatitis B Liver cancer Clinical efficacy |
| 基金项目:辽宁省科学技术基金（20170541001） |
|
| 摘要点击次数: 1302 |
| 全文下载次数: 1188 |
| 中文摘要: |
| 目的：观察槐耳颗粒联合吡柔比星介入治疗乙型肝炎病毒（HBV）DNA阴性的乙肝肝癌患者的临床疗效并记录其不良反应。方法：选取2012年2月至2016年2月（随访时间为1年）在中国医科大学附属第一医院肝胆外科住院符合临床研究标准的HBV DNA阴性的肝癌患者120例（完成临床研究且临床资料数据可靠的96例），随机分为干预组与对照组，每组60例。对照组给予介入治疗（盐酸吡柔比星+超液化碘油）+替恩卡韦（抗病毒治疗）+常规保肝治疗；干预组在对照组的基础上给予槐耳颗粒治疗，2组均连续治疗6个月。治疗后比较2组的临床疗效、HBV DNA定量、肝酶、免疫学指标。结果：治疗后干预组近期及远期临床疗效均优于对照组（P<0.05），治疗前2组的肝酶、HBV DNA定量、免疫学指标差异无统计学意义（P>0.05），治疗后2组的肝酶、HBV DNA定量较治疗前有所降低（P<0.05），且干预组低于对照组（P<0.05），治疗后2组的免疫学（细胞免疫、体液免疫）指标均优于治疗前（P<0.05），且干预组优于对照组（P<0.05）。2组治疗中均出现白细胞降低、血小板计数降低、恶心、呕吐等不良反应。结论：槐耳颗粒联合介入治疗能很好的提高乙肝肝癌的临床疗效，且不良反应少。 |
| English Summary: |
| To observe the clinical efficacy of Huaier granule combined with interventional treatment on patients with HBV DNA-negative Hepatitis B and record the adverse reaction. Methods:A total of 120 liver cancer patients with HBV DNA-negative Hepatitis B were randomly divided into intervene group and control group, with 60 patients in each group. Control group received intervention, percutaneous puncture of femoral artery, then injected Pirarubicin hydrochloride for injection + lipiodol in parent artery until blood stagnation + antivirus (entecavir), and also conventional liver protection therapy was conducted; intervene group additionally received Huaier granule for continuous 6 months. Clinical efficacy, HBV DNA quantification, and liver function indexes in the two groups were compared. Results:After treatment, short and long-term clinical efficacy in observation group was significantly better than the control group (P<0.05). Before the treatment, there were no significant differences in HBV DNA quantification and liver function (P>0.05). After treatment, the HBV DNA quantification and liver function were both lower than before treatment in both groups (P<0.05), and the HBV DNA quantification and liver function were lower in the intervene group than control group (P<0.05). After treatment, the cell-mediated immunity and humoral immunity were both better than before treatment in both groups (P<0.05), and the cell-mediated immunity and humoral immunity were better in the intervene group than control group (P<0.05). During the treatment, reducing leucocyte and platelet, nausea, vomit, etc. were occuring in both groups. Conclusion:Huaier granule combined with interventional treatment on patients with HBV DNA-negative Hepatitis B can improve the clinical efficacy, with less side effects. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
